Now showing items 21-30 of 90
Longer Patents for Increased Genetic Competition: The Waxman-Hatch Act After One Decade
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act
IN 1984, Congress enacted a new law that greatly affected the economics of the pharmaceutical industry in the United States. It has been characterized as the most important legislation affecting competition in the pharmaceutical ...
Does generic entry always increase consumer welfare?
(Food Drug Law J, 2012)
This article examines how the nature of competition between brands in a therapeutic category changes after generic entry and provide a framework for analyzing the effect of generic entry on consumer welfare that takes into ...
Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures
Pharmaceutical R&D competition in the 1980s and 1990s was characterized by rising R&D expenditures, favorable returns to innovators, and the introduction of many new classes of drugs with high social benefits. However in ...
How did the 2003 prescription drug re-importation bill pass the house?
(Economics and Politics, 2006-03-01)
We examine the major interest groups in the debate over allowing the re-importation of prescription drugs by utilizing a logit model and instrumental variables. Consistent with political support approach, the evidence suggests ...
Returns to R&D on new drug introductions in the 1980s.
(J Health Econ, 1994-12)
This study finds that the mean IRR for 1980-84 U.S. new drug introductions is 11.1%, and the mean NPV is 22 million (1990 dollars). The distribution of returns is highly skewed. The results are robust to plausible changes ...
PIONEERS, IMITATORS, AND GENERICS - A SIMULATION-MODEL OF SCHUMPETERIAN COMPETITION
(QUARTERLY JOURNAL OF ECONOMICS, 1987-08)
The Role of Cost-Effectiveness Analysis in Managed Care Decisions
Determinants and Distributional Aspects of Enrollment in U.S. Higher Education
(Journal of Human Resources, 1972-12)
Economic Evaluation of Drug Treatment for Psychiatric Disorders: The New Clinical Trial Protocol
(Psychopharmacology: the Fourth Generation of Progress, 1995)